<DOC>
	<DOCNO>NCT01296087</DOCNO>
	<brief_summary>This study design determine whether TC-6987 improve respiratory function subject asthma reduce airway hyper-responsiveness inflammation .</brief_summary>
	<brief_title>TC-6987 Treatment Mild Moderate Asthma</brief_title>
	<detailed_description>Asthma common , chronic inflammatory disorder airway affect estimate 20 22 million people United States . It characterize variable recur symptom , notably airflow obstruction , bronchial hyperresponsiveness , underlie inflammation . The bronchospasm cause inflammation muscle surround air passageway , make small , thus difficult air freely move lung . Cardinal symptom asthma include cough , chest tightness , shortness breath wheezing . These symptom often severe morning late night , usually reversible medication . Clinically , asthma typically classified accord frequency symptom , force expiratory volume 1 second ( FEV1 ) , peak expiratory flow rate . The rationale Phase II proof concept study demonstrate TC-6987 improves respiratory function subject asthma , compare placebo , measure Baseline FEV1 Day 1 compare End-of-Treatment FEV1 Day 28 Early Withdrawal ( EW ) ; also assess safety tolerability profile TC-6987 subject asthma .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>1 . A clinical diagnosis persistent mild moderate asthma require least 3 month daily treatment inhaled corticosteroid ( ICS ) . 2 . A FEV1 value Screening 6090 % predict FEV1 . 3 . Age 18 65 , male female . 1 . Diagnosis presence pulmonary disease include chronic obstructive pulmonary disease ( COPD ) emphysema . 2 . Previous lifethreatening asthma , asthma require intubation ICU admission asthma . 3 . Prolonged hospitalization asthma within past year ( emergency room treatment use nebulized betaagonists permit ) . 4 . Not able willing stop use longacting betaagonists ( LABAs ) , cromolyn sodium , methylxanthines , anticholinergic agent , leukotriene inhibitor , nonICS nonSABA prescription overthecounter antiasthma medication , include antihistamine , Screening Study . 5 . Use moderate strong cytochrome P450 3A4 ( CYP3A4 ) inhibitor . 6 . Use oral steroid within last 1 month , use &gt; /= 3 steroid burst last 12 month . 7 . History upper respiratory tract infection ( URI ) require treatment last month prior Screening . 8 . Tobacco use within 3 month prior Screening , &gt; 5 packyear lifetime tobacco use . 9 . Use smoke cessation therapy within 3 month prior Screening . 10 . Uncontrolled Gastroesophageal reflux disease ( GERD ) . Subjects stable dose nonprescription prescription medication symptom free 4 wks prior screen eligible . 11 . History within past 6 month alcohol abuse illicit drug abuse . 12 . Myocardial infarction within 12 month prior Screening . 13 . Known hypothyroidism , vitamin B12 , folic acid deficiency . 14 . Known systemic infection ( HBV , HCV , HIV , TB ) . 15 . FSH level &lt; 35 IU/L LH level &lt; 25 IU/L . 16 . Urine cotinine level &gt; 50 ng/ml . 17 . Body Mass Index ( BMI ) &lt; 15 &gt; 35 . 18 . Participation another clinical trial past 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Mild Moderate Asthma</keyword>
</DOC>